SAB BIO

Sanofi has high hopes for its anti-CD3 antibody therapy, Tzield, in delaying the progression of type 1 diabetes but despite achieving its primary biomarker goal, its latest Phase III has fallen short

The chances of Synairgen bringing its inhaled COVID-19 candidate to market have dwindled after a failure in a hospital-based Phase III trial. The Southampton, UK-based company has been developing it

Mergers with special purpose acquisition corporations (SPACs) have become lucrative financial transactions for biopharmaceutical firms because they can raise significant capital and become publicly tr

As venture capital financings for biopharmaceutical companies continues to head into record-breaking territory again in 2021, Illumina Ventures and Jeito Capital announced two new venture capital fund